期刊文献+

脉络宁对COPD患者ET含量的变化观察

Effect of Chronic Maluoling Treatment on Plasma Contents of ET in Patients with COPD
下载PDF
导出
摘要 目的:探讨脉络宁对慢性阻塞性肺病(chronic obstructive pulmonary diseases,COPD)患者血浆内皮素(endothelin,ET)含量变化的影响。方法:选择COPD患者45例在脉络宁应用前及一年时分别测定血浆ET含量为观察组;同期未应用脉络宁的COPD患者为对照组,同时测定ET含量。采用放免法(RIA)测定血浆ET含量。结果:观察组由治疗前(80.49±29.67)pg/ml至一年时(64.38±24.5)pg/ml;对照组(78.28±24.38)pg/ml至一年时(77.49±30.63)pg/ml。二组治疗前对比无差异(P>0.05)。应用后,一年时对比有显著性差异(P<0.05)。结论:脉络宁对COPD患者具有调节血浆ET使其减少的作用。 Objective To study the effect of maluoling treatment on plasma ET eonents in patients with COPD. Methods Plasma ET contents were measured with RIA at admission one year later in (1) 45 patients with COPD treated with 4 courses of maluoling and (2) 82 patients with COPD without maluoling treatment. Results The plasma ET contents in the two groups of COPD patients were not much different at admission (80.49 ± 29.67pg/ml vs 78.28 ± 24.38pg/ml, P 〉 0.05). One year later, the plasma ET contents in the 45 patients with maluoling treatment were significantly lower than those in the 32 patients without maluoling treatment (64.38 ± 24. 52pg/ml vs 77.49 ± 30.63pg/ml, P 〈 0.05). Conclusion Chronic use of maluoling could markedly decrease the plasma ET contents in patients with COPD.
出处 《放射免疫学杂志》 CAS 2008年第1期35-37,共3页 Journal of Radioimmanology
关键词 脉络宁 慢性阻塞性肺疾病 内皮素 maluoling, chronic obstructive pulmonary diseases, endthelin
  • 相关文献

参考文献13

二级参考文献20

  • 1辛晓峰,施毅.支气管哮喘和慢性阻塞性肺疾病气道重塑的差异[J].中国实用内科杂志,2006,26(8):1195-1197. 被引量:14
  • 2Channick RN, Sitbon O, Robbins I, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension : a randomised placebo-controlled study. Lancet, 2001,358(9288) :1119-1123.
  • 3Rubin LJ, Badesch DB, Barst RJ,et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med ,2002,346 (12) :896-903.
  • 4Galie N, Adam T, Thierry F, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol,2003,41 ( 8 ) : 1380-1386.
  • 5Rubens C ,Halank M,Wensel R,et al. Endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest,2001,120 ( 5 ) : 1562-1569.
  • 6Yamamoto K,Ikeda U, Mito H,et al. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation,1994,89(5) :2093-2098.
  • 7Celli BR, MacNee W, ATS/ERS Task Force.Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
  • 8Kitarnura K, Kangawa K, Kawarnoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocyteoma[J]. Biochem Biophys Res Commun, 1993,192:553 - 560.
  • 9Kamoi H, Kanazawa H, Hiratak K, et al. Adrenomedullin inhibit the secretion of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, from rat alveolar macrophagas[ J ]. Biochem Biophys Res Commun, 1995,211 : 1301 - 1035.
  • 10Nossaman BD, Feng C J, Cheng DY, et al. Comparative effects of adrenomedullin analog and CGRP in the pulmonary vascular bed of the eat and rat[J]. Life Sci,1995,56:63 -66.

共引文献292

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部